血友病A.patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of血友病A.发达市场预防性治疗的需求增长将对这一市场产生很大影响。
根据美国疾病控制和预防中心，血友病发生在5,000个活的男性出生中发生。血友病A大约是血友病B.美国血友病血友病的人数估计为约20,000人。大约75％的世界各地血友病仍然接受治疗不足或无法获得治疗。
As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.
Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.
有问题吗？在通过单击下面的链接，请在购买此报告之前请求示例或进行查询：
//m.ptlymt.com/Industry-analysiss/hemophilia-a-treatment-market.
RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.
Polaris Market Research has provided the forecasts of the Global Hemophilia A Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:
- Market Analysis by Hemophilia A treatment
- 护理/销售药物的市场分析
- G7国家的市场分析
2016 - 2016 - 2016年预测中的市场疗法是：
- Afstyla销售预测 - 2016-2022
- ELOCTATE销售预测 - 2016-2022
- Hemlibra销售预测 - 2016-2022
- Kogenate FS Sales Forecast-2016-2022
- Kovaltry Sales Forecast-2016-2022
- NuWIQ销售预测 - 2016-2022
- obizur销售预测 - 2016-2022
这血友病A治疗区域的主要适应症：
- 预防 - 市场预测2016-2022
- On-demand therapy-Market Forecast 2016-2022
- Inhibitor therapy- Market Forecast 2016-2022
这Market Forecast of Hemophilia A Treatment by G7 Countries (2016-2022)
- United States- Market Forecast (2016-2022)
- 德国 - 市场预测（2016-2022）
- 法国市场预测（2016-2022）
- 意大利 - 市场预测（2016-2022）
- 西班牙- Market Forecast (2016-2022)
- 英国 - 市场预测（2016-2022）
- 日本 - 市场预测（2016-2022）
Leading Companies investigated in the Report are
- CSL Behring.
- 嘉
- 拜耳
- Biogen
- Genentech.
- Bioverativ.
- alnylam pharmaceuticals.
- Sanofi（Genzyme）
- BioMarin Pharmaceutical
- Hoffmann-la Roche
- Sinocelltech Ltd.
- 江苏嘉大泰天清药业有限公司
- 十二章
- LFB USA, Inc.
- novo nordisk a / s
- Pfizer